ReviewCells2026
Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Experimental and In-Silico Analysis Indicates Melittin as a Modulator of IL-37a-Associated Networks in Neuroblastoma.The protein journal · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Neuroblastoma is the most common extracranial solid tumor in children, and the prognosis for high-risk patients remains dismal. Immunotherapies, represented by anti-GD2 monoclonal antibodies and chimeric antigen receptor T cells (CAR-T), have significantly improved the survival of high-risk neuroblastoma patients and become part of standard therapy. However, their efficacy exhibits significant inter-individual heterogeneity, with some patients showing primary resistance or secondary relapse. This review aims to analyze the multi-faceted factors influencing the response to immunotherapy in neuroblastoma, including: (1) the inherent immunosuppressive properties of the tumor microenvironment, such as infiltration of myeloid-derived suppressor cells and tumor-associated macrophages, as well as checkpoint molecules and metabolic barriers; (2) tumor cell-intrinsic characteristics, such as low tumor mutational burden,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.